SarahChen_PharmD said:

The pattern that distinguishes a bad batch from an exit is behaviour rather than product.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

BiostatsBrad said:

Steady state is the thing most people miss.

Thank you for spelling out the reasoning rather than just the conclusion. Adding it to my notes with a link back to this thread.

SarahChen_PharmD said:

The pattern that distinguishes a bad batch from an exit is behaviour rather than product.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

One concrete data point for the thread. Red flags, in rough order of how much they should worry you: no verifiable address, no batch numbers, prices far under market, vendor-commissioned tests only, pressure toward irreversible payment, and shipping with no temperature control.

Worth separating that from vendor vetting, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

I would rather be corrected than agreed with, if it comes to it.

Moderator note: a couple of off-topic posts removed. Report rather than reply if it drifts again.